Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

J Acquir Immune Defic Syndr. 2007 May 1;45(1):1-3. doi: 10.1097/QAI.0b013e318046ea31.

Abstract

The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12% before screening to 0% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2% to 0.73%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Black People / statistics & numerical data
  • Dideoxynucleosides / adverse effects*
  • Dideoxynucleosides / therapeutic use
  • Female
  • France / epidemiology
  • France / ethnology
  • Genetic Testing*
  • HIV
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HLA-B Antigens / genetics*
  • Humans
  • Hypersensitivity / genetics
  • Hypersensitivity / prevention & control*
  • Incidence
  • Male
  • Middle Aged
  • Polymerase Chain Reaction / economics
  • Polymerase Chain Reaction / methods
  • Predictive Value of Tests
  • Prospective Studies
  • Retrospective Studies
  • Sensitivity and Specificity
  • Suburban Population
  • Urban Population
  • White People / statistics & numerical data

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • abacavir